only you for call, Thank the Dominik. not second Welcome, Thank for first joining everyone. but us call. the you, for today,
number my determined to I care of tell as remarks, health services two prepared how as America's by have we say Before Newsweek. proud and been loved most and like recognized begin workplaces I am that you I'd
patients for do. gratitude for jobs and pandemic presentation, my even if and the begin accept with innovating, one you Our out third incredible fantastic a the my job and that start caring, please please, in each will. let's products will four, employees there, all slide delivering situation over and the and thanks you our producing every prepared during remarks quarter you world with do I of this
the this world, increased patient stronger-than-projected During headwind, as a faced starts mortality the growth third new we We've a the delivered our from the in headwind of of us that fact, significant effects X%. the drivers quarter, underlying of of global result and patient trend variant. COVID around in which spread quarter Despite the significantly a organic Delta business as reversed solid tells number seen very intact. are, access
year guidance. are We confirming XXXX full our
resources strategic are ensuring that the in the the patients due on projected priorities, we makes Significant net revenue ranges COVID that life-sustaining right need. all our than now now. industry more the expect in quarter. mortality. progress at continued of That receive treatments our our income However, dialysis the continue to rightfully our they the impressive higher a and is excess significantly on focused end to lower come to for challenge
to value and First, I just for in update. this are not savings, look QX in business, discussing there terms Please FMEXX excited of future potential following will really our but business. Helen we mean hang our FMEXX for about us. the extremely unlocking of further with what both and forward growth
of the you quarter. home the a on treatments efforts the third the setting so the consider Secondly, the in more pandemic level XX% and even spent by is a This crossed performed great in achievement managing US. have in our we when quarter, all of within team
and given management US. training important able current we're growth very very obviously, priority home, the from continue, a about home to are be will are potential for as pandemic in patients especially interested the to the to optimistic shift the back situation This treatments. labor many in continued experiencing we We resources that
the capabilities. addressable move market medical to Alone and US$XX X billion. since of our with continuing US, are significant managed kidney XXXX. in value-based up the and is billion the care more market in leading for patients built disease we We've than have X US$XX cost Thirdly, Stage around chronic experience
this US$X.X medical costs roughly lives. billion year, around of and we managed While covered XX,XXX
Charlotte. X.X% CMS to rule QIP the penalties X:XX sustainability eliminate few be XX global to progress we the the and to important Friday, start that our management finally, our by has Maddux, CET, track for this will expect hope Global Officer XXXX Dr. finalized on I'll public join Head health On rule emergency. payment with time care. or $X.XX. able the last costs for host XXXX and US$X are CKCC With treatment, the prospective you final ESRD an against The in COVID-XX And exceed light With are billion. for our November was proposal a at under that sustainability some patient-centered making spend an and Stange, final in call of medical ongoing in months, published Charlotte and Frank improved increase Frank the expert models initiatives. we the Sustainability Medical will on p.m. CMS. our just time original sustainability to of Chief leave proposal. system per then update with Fourthly, Global $XXX.XX of us
to Turning five. slide
clinic to in negative clinics The mainly so our of North ago. and number the months about a to way the this pandemic of over to dialysis year, the The of of During and to of patients. patients. number the treatments million XX X impact the XX COVID-XX were America lives is growth relates many tragic in or around to directly that many, XXX,XXX in X% acquisitions relates opened first we've months growth patients newly treatments delivered decrease that touched and XX initiated the due
Turning six. to slide
mineral our infections This patients that have the number to population. patient of Fresenius demonstrating across see bone consistent metabolism Medical development are to well to seen we of our high-quality the control, worldwide turn We Care compares receiving pandemic. the during care continue COVID slide even stable anemia as cases dialysis slide and as Please seven.
As the COVID increased extended mortality and seen vaccines provided. mitigation Delta variant wave with of of fourth morbidity to general with the pandemic has and viral protection the have leading population, phase the that the the this illness, despite
rates seen have declining end last However, we of quarter. the since infection
of be all that advocate to continue patients vaccinated. our We
despite increases We least in one vaccination the of United XX% And and QX with received known rates our results our of in cases. vaccines globally, necessary. patients United patients with patients doses both in have the the vaccinated We dose. our compared States, of one at our the around to end of unvaccinated the The since fully States only have benefit COVID vaccinated third distinct patients rate one same at to both July. provided breakthrough Today, communities. where to majority half the seen in are have see of our patients
encouraging our vaccinated are boosters. to receive patients We
vaccines, US BionTech, see the in the pickup that Now are as J&J has rates Pfizer, booster a approved we well. boosters Moderna to starting for and
dose in of by our holiday does indoor campaign active to it, all holiday the booster patients have as to a when Thanksgiving receive vaccinated like an begin. the weeks US to season the before we November have XX, two refer We
evolve, become the pandemic how While predict hard more should general vaccine the there ultimately will the be a time, will it approval population COVID will condition. This for will And are signs years have that it broader COVID looks support manageable people In pandemic X is more and herd immunity. endemic. medical more been to reality. is based the to at infected This and immunity. same developed and community older their a own children becoming make
eight. Moving to slide
months hit never trended excess levels pre-pandemic we mortality the year, During of downwards, hoped. reaching had X the the as first
the within trend the saw the the infection of level With of seen mortality background rates over general the the The the local globe. in with curve the reversal level the approximately globally we at throughout Excess summer, quarter. country population again global excess third spread mortality and increasing quarter. variant and of a both X,XXX reached mortality this Delta throughout state local mimic
the last the Globally, lesser in During accumulated XX,XXX. the North excess deaths since further particularly quarter, America extent, third to and them seen a basis, XX,XXX pandemic, in EMEA. we've start of impact month was approximately pronounced the XX approximately on to to a accumulate
cases new we level of projecting saw in quarter we to declining, COVID mortality fourth below are somewhat As the third excess the be quarter.
in Turning we the to third reflecting €X.X currency. revenue nine. growth constant X% of slide quarter, billion, achieved In
the items, €X to related will FMEXX Our treated declined And million Costs basis. as special item. costs we excluding FMEXX a related third special pretax. net by currency quarter, constant on a income, be had in during XX%
line. bottom our already the pandemic impacted mentioned, negatively top and As
a net quarter net €XXX million. third Our income effect includes COVID negative of
third income approximately above quarter impact, would have the this growth Excluding net our XXXX been X% base. in the
face inflationary continuing macroeconomic pressures also labor to We are related the and in raw materials quarter. to both
third effect. were impacted by a negative quarter exchange Our foreign slightly earnings
during Turning positively. timing region of we with to North only EMEA, in the detail. all who'll to by third that, take to hindered COVID, development sales. America, the In growth Latin XX. slide the and related not organic Asia Despite organic the delivered quarter challenges America, pandemic, faced Pacific growth over I'll negative the turn you it growth greater impacts but some also through was export the from in Helen, With contributing
